ADAPTIVE BIOTECHNOLOGIES CORPORATION Pay versus Performance
The Pay versus Performance table from each proxy statement (Item 402(v)), as tagged in its XBRL, newest proxy first. Each proxy's own figures are kept, so a year restated in a later proxy appears once per proxy. PEO is the principal executive officer; NEO means the other named executive officers (average). Total shareholder return is the value of a $100 investment.
- 2025-12-31: PEO Mr. Robins; PEO total compensation $9.08M; PEO compensation actually paid $39.60M; Other NEO average total compensation $4.99M.
- 2024-12-31: PEO total compensation $4.97M; PEO compensation actually paid $8.35M; Other NEO average total compensation $2.39M.
- 2023-12-31: PEO total compensation $8.90M; PEO compensation actually paid $2.75M; Other NEO average total compensation $4.26M.
- 2022-12-31: PEO total compensation $8.85M; PEO compensation actually paid -$1.14M; Other NEO average total compensation $4.32M.
| Fiscal year end | PEO | PEO total compensation | PEO compensation actually paid | Other NEO average total compensation | Other NEO average compensation actually paid | Total shareholder return | Peer group total shareholder return | Net income | Company-selected measure | Proxy filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Mr. Robins | $9.08M | $39.60M | $4.99M | $18.38M | $27.00 | $125.00 | Revenue $276.98M | 2026-04-24 | |
| 2024-12-31 | $4.97M | $8.35M | $2.39M | $569.71K | $10.00 | $93.00 | $178.96M | 2026-04-24 | ||
| 2023-12-31 | $8.90M | $2.75M | $4.26M | $1.36M | $8.00 | $94.00 | $170.28M | 2026-04-24 | ||
| 2022-12-31 | $8.85M | -$1.14M | $4.32M | -$2.58M | $13.00 | $90.00 | $185.31M | 2026-04-24 | ||
| 2021-12-31 | $8.75M | -$6.18M | $5.87M | -$3.11M | $47.00 | $100.00 | $154.34M | 2026-04-24 | ||
| 2024-12-31 | Mr. Robins | $4.97M | $8.35M | $2.39M | $569.71K | $20.00 | $118.00 | -$159.59M | Revenue $178.96M | 2025-04-29 |
| 2023-12-31 | $8.90M | $2.75M | $4.26M | $1.36M | $16.00 | $119.00 | -$225.30M | $170.28M | 2025-04-29 | |
| 2022-12-31 | $8.85M | -$1.14M | $4.32M | -$2.58M | $26.00 | $114.00 | -$200.37M | $185.31M | 2025-04-29 | |
| 2021-12-31 | $8.75M | -$6.18M | $5.87M | -$3.11M | $94.00 | $126.00 | -$207.30M | $154.34M | 2025-04-29 | |
| 2020-12-31 | $7.13M | $24.87M | $4.13M | $14.49M | $198.00 | $126.00 | -$146.23M | $98.38M | 2025-04-29 | |
| 2023-12-31 | Mr. Robins | $8.90M | $2.75M | $4.26M | $1.36M | $16.00 | $119.00 | -$225.30M | Revenue $170.28M | 2024-04-26 |
| 2022-12-31 | $8.85M | -$1.14M | $4.32M | -$2.58M | $26.00 | $114.00 | -$200.37M | $185.31M | 2024-04-26 | |
| 2021-12-31 | $8.75M | -$6.18M | $5.87M | -$3.11M | $94.00 | $126.00 | -$207.30M | $154.34M | 2024-04-26 | |
| 2020-12-31 | $7.13M | $24.87M | $4.13M | $14.49M | $198.00 | $126.00 | -$146.23M | $98.38M | 2024-04-26 | |
| 2022-12-31 | Mr. Robins | $8.85M | -$1.14M | $4.32M | -$2.58M | $26.00 | $114.00 | -$200.37M | Revenue $185.31M | 2023-04-28 |
| 2021-12-31 | $8.75M | -$6.18M | $5.87M | -$3.11M | $94.00 | $126.00 | -$207.30M | $154.34M | 2023-04-28 | |
| 2020-12-31 | $7.13M | $24.87M | $4.13M | $14.49M | $198.00 | $126.00 | -$146.23M | $98.38M | 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |